Every year, approx. 40,000 people suffer from sepsis in Sweden. Totally, worldwide between 47-50 million people are affected, of which approx. 11 million die from sepsis. (www.globalsepsisalliance.org)
Aptahem AB develops drugs for the treatment of acute life-threatening conditions where Apta-1, the company’s main candidate, is under development and intended as an emergency drug to prevent the occurrence of organ and tissue damage in patients suffering from sepsis.
To notice the WSD, Aptahem hosted an online Sepsis Seminar on September 13.
|Aptahem introduction||Mikael Lindstam, CEO Aptahem|
|Sepsis; clinical manifestations, treatment and ongoing research||Mats Eriksson, Associate Professor, Section of Anesthesiology and Intensive Care, Department of Surgical Sciences, Uppsala University, Sweden|
|Sepsis – Laboratory diagnostics
A focus on neutrophils
|Anders Larsson, Professor, Department of Clinical Chemistry and Pharmacology, Uppsala University, Sweden|
|Future diagnostics of sepsis – SepsIT®||Anna-Karin Pernestig, Associate Professor in Biosciences, University of Skövde, Sweden|
|Aptahem – ongoing research:|
|Apta-1 – a drug candidate to fight sepsis||Luiza Jedlina, PhD, CSO Aptahem|
|Apta-1 and Covid-19||Mingyao Liu, MD, Senior Scientist, Toronto General Hospital Research Institute, Canada|
|Sepsis meeting Apta-1 and Haemostasis||Magnus Grenegård, Professor, School of Medical Sciences, Örebro University, Sweden|
|Closure||Mikael Lindstam, CEO Aptahem|